Review ArticleIndian Journal of Pharmaceutical Education and ResearchVol. 55 | Issue 2 | 2021 | pp. 336–345Open access
Overview of FBO Licensing in the India and New Dietary Ingredient Notification in the US
- 1,
- 2*,
- 3
- 1 Pharmaceutical Regulatory Affairs, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagar, Mysuru, Karnataka, INDIA.
- 2 Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagar, Mysuru, Karnataka, INDIA.
- 3 JSS College of Pharmacy, JSS Academy of Higher Education and Research. Sri Shivarathreeshwara Nagar, Mysuru, Karnataka, INDIA.
Published in Indian Journal of Pharmaceutical Education and Research
Correspondence: MP Venkatesh
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagar, Mysuru, Karnataka, INDIA.
Email: venkateshmpv@jssuni.edu.in
Copyright: © 2021 Manuscript Technomedia. This is an open access article.
- Published:
- Jan 1, 2021
- Received:
- Jul 15, 2020
- Accepted:
- Feb 9, 2021
- DOI:
- 10.5530/ijper.55.2.71
How to cite
B, N., Venkatesh, M., & Kumar, T. P. (2021). Overview of FBO Licensing in the India and New Dietary Ingredient Notification in the US. Indian Journal of Pharmaceutical Education and Research, 55(2), 336–345. https://doi.org/10.5530/ijper.55.2.71
Abstract
The nutraceuticals in India are termed as "Foods for Special Dietary Uses" Food Safety and Standards Authority describes "Nutraceuticals provide a physiological benefit and help to maintain good health." FSSAI was recognized in India under the 2006 Food Safety and Standards Act, combines several acts and guidelines that existed in various ministries and departments to deal with food related substances. In US regulation, dietary supplements define “dietary supplement in part as product taken by mouth that contain a dietary ingredient. Dietary ingredients include nutrients, minerals and vitamins amino acids and herbs or botanicals and many other ingredients that can be used to enhance the diet. Demand for nutraceuticals is growing day by day, it has been noted that around 60-70% of dietary supplements marketed in India are false, counterfeit, unsecured and unauthorized. It is a problem that has not gone unnoticed by both the regulator and the industry. To take advantage of this demand, many new companies have begun manufacturing nutraceuticals. FSSAI has defined regulatory guidelines for approval of nutraceuticals in the Indian market. The aim of this article to have a closer look at nutraceuticals and their Food Business Operator (FBO) licensing, registration procedure and FSSAI key criteria for manufacturing nutraceuticals in India compared to US dietary supplement, submission and approval of NDI notification for New Dietary Ingredient. The nutraceutical industry has now developed into a growing organization fuelled by intense efforts to identify nutraceutical product characteristics and prospective applications, combined with customer demand and requirements.
Keywords
Subject
Article metadata
| Title | Overview of FBO Licensing in the India and New Dietary Ingredient Notification in the US |
|---|---|
| Authors | Nandhini B; MP Venkatesh; TM Pramod Kumar |
| Affiliations | Pharmaceutical Regulatory Affairs, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagar, Mysuru, Karnataka, INDIA.; Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagar, Mysuru, Karnataka, INDIA.; JSS College of Pharmacy, JSS Academy of Higher Education and Research. Sri Shivarathreeshwara Nagar, Mysuru, Karnataka, INDIA. |
| Corresponding author | venkateshmpv@jssuni.edu.in |
| Journal | Indian Journal of Pharmaceutical Education and Research |
| Volume / Issue | Vol. 55, Issue 2 (2021) |
Also in this issue
- Artificial Intelligence in Pharmacypp. 304–318
- Possible Insights into the Use of Silver Nanoparticles in Targeting SARS-CoV-2 (COVID-19)pp. 319–329
- An Overview of Dual Targeting Nanostructured Lipid Carriers for the Treatment of Ovarian Cancerpp. 330–335
- Targeted Drug Delivery System: Advantages, Carriers and Strategiespp. 346–353
- Formulation and Characterization of Chitosan Microparticulate System Using Central Composite Design for the Drug: Lafutidinepp. 354–362